Business Atlas

How Enterprise Is Built
Sign In
Text size
100%
Theme
Founders, Executives and Management Thinkers

Daniel Vasella

Founder and Executive

Daniel Vasella (born 1953) is a Swiss medical doctor and executive who was chief executive and later chairman of the pharmaceutical company Novartis. Born in Fribourg, he took his medical degree at the University of Bern in 1980, then moved into the drug industry, joining the American arm of Sandoz in 1988 and becoming chief executive of Sandoz Pharma in 1992. He helped arrange the 1996 merger of Sandoz and Ciba-Geigy that created Novartis and was named chief executive of the combined company, then chairman of its board in 1999. He gave up the chief executive post in January 2010 and left the chairmanship in February 2013, when a large payment tied to his departure drew public criticism. Time named him one of the world's 100 most influential people in 2004.

Connections

Associated With

Source Daniel Vasella (Wikipedia)
Source Daniel Vasella (Wikipedia)

Led By

Source Daniel Vasella (Wikipedia)
In the Other Atlases

Nationality

Also in Geography Atlas: the nationality of this subject.

Source Daniel Vasella (Wikipedia)Lead paragraph [nationality]
Quote, Lead paragraph [nationality]
is a Swiss medical doctor, author, and executive
Sources
Daniel Vasella (Wikipedia)
  • Lead paragraph [nationality]
    is a Swiss medical doctor, author, and executive
  • Associated With: Leadership, Career
    He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd.
  • Led By: Novartis, Career [led-by]
    Vasella was appointed CEO of the combined entity and a member of the board of directors.
  • Associated With: Pharmaceutical Industry, Lead paragraph
    CEO and chairman of the Swiss pharmaceutical company Novartis AG
  • In Group: Chief Executives and Senior Executives, Lead section
    who was CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company
View the Source

Take a Related Quiz

Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.